Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1994-05-17
1995-10-31
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
A61K 3166, A61K 31685
Patent
active
054629322
ABSTRACT:
Disclosed is a therapy protocol for treating and for preventing bone loss in patients who have difficulty in swallowing by administering a liquid formulation of alendronate which can be easily swallowed. Also described are pharmaceutical dosage forms of a syrup, aqueous solution, a solution formed from a reconstituted powder, of alendronate, for carrying out the therapeutic method.
REFERENCES:
patent: 4922007 (1990-05-01), Kieczykowski et al.
patent: 5002937 (1991-03-01), Bosies
patent: 5019651 (1991-05-01), Kieczykowski
patent: 5227506 (1993-07-01), Saari et al.
patent: 5270365 (1993-12-01), Gertz et al.
patent: 5356887 (1994-10-01), Brenner et al.
patent: 5376649 (1994-12-01), Pohjala et al.
Brenner Gerald S.
Katdare Ashok V.
Pretzer Denise
Whiteford Donna T.
Giesser Joanne M.
Merck & Co. , Inc.
North Robert J.
Raymond Richard L.
Winokur Melvin
LandOfFree
Oral liquid alendronate formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral liquid alendronate formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral liquid alendronate formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1772334